Dr. Heidi Overton appeared before the Senate Health, Education, Labor, and Pensions (HELP) committee on Thursday for her confirmation hearing to serve as the next Food and Drug Administration commissioner. Nominated by President Donald Trump in August, she was praised on social media as a “ROCKSTAR in my Administration.”
Overton is expected to face intense questioning regarding her positions on childhood immunizations and mifepristone, the medication used for medical abortions. If confirmed, she will succeed Marty Makary, who resigned earlier this year after public disputes with lawmakers, pharmaceutical companies, and the president over regulations on fruit-flavored vaping products. Kyle Diamantas has served as acting commissioner since May 2026.
During a recent CNBC interview, Scott Gottlieb, who served as FDA commissioner during Trump’s first term, voiced confidence that Overton possesses the resilience to rebuild the agency following recent staffing reductions.
Overton currently serves as the deputy director of the White House Domestic Policy Council and previously acted as Trump’s deputy assistant for domestic policy, where she advised on health initiatives such as reducing prescription drug costs. She has frequently stood beside the president at major White House health announcements, including an executive order signed in August concerning the childhood vaccine schedule.
Described by sources as a loyalist to the president, Overton has advocated for anti-abortion measures and supported cuts to the childhood immunization schedule. During the August executive order signing, she emphasized the use of “gold-standard science” and argued for restoring vaccination decision-making authority to parents.
A former senior administration official noted that her nomination was driven by her loyalty, stating, “She kind of goes along with things,” while acknowledging her long career in politics.
Overton holds a medical degree from the University of New Mexico and a doctorate from Johns Hopkins University. Before joining the Trump administration, she served as chief policy officer and vice chair of the Center for a Healthy America at the America First Policy Institute (AFPI), a nonprofit also led by Agriculture Secretary Brooke Rollins prior to her Cabinet appointment.
Sen. Bill Cassidy, R-La., chair of the HELP committee, expressed strong reservations about the nomination due to Overton’s involvement in the executive order modifying the vaccine schedule. “That alone is almost disqualifying,” Cassidy wrote on X. A physician himself, Cassidy has previously questioned the willingness of health officials to oppose Health and Human Services Secretary Robert F. Kennedy Jr.
The role of the FDA in regulating mifepristone remains a contentious issue. Last year, Kennedy initiated a safety review of the drug. Democratic Women’s Caucus Chairwoman Teresa Leger Fernández called for the Senate to reject the nomination, alleging that Overton has denied scientific facts and attacked abortion access and the safety of Planned Parenthood services.
Dr. Amesh Adalja, a senior scholar at the Johns Hopkins University Center for Health Security, also criticized the selection. He cited concerns over Overton’s central role in shrinking the vaccine schedule without new evidence and her alignment with Secretary Kennedy, describing the latter as the nation’s “chief anti-vaccine propagandist.”
The mifepristone question is going to be a huge hurdle. It’s not just about ideology; it’s about regulatory stability.
Will she have any real independence if she was chosen purely for loyalty? The FDA needs scientific rigor, not political obedience.
I’m surprised they appointed someone with such clear anti-vaccine leanings to lead the FDA. Doesn’t that undermine public trust?
As a mother, I support giving parents more say in their children’s vaccines. Science should guide policy, not politics.